| Natural history and real‐world data in rare diseases: applications, limitations, and future perspectives J Liu, JS Barrett, ET Leonardi, L Lee, S Roychoudhury, Y Chen, P Trifillis The Journal of Clinical Pharmacology 62, S38-S55, 2022 | 66 | 2022 |
| Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders VP Reddy, M Kozielska, M Johnson, A Vermeulen, R de Greef, J Liu, ... Clinical pharmacokinetics 50, 429-450, 2011 | 52 | 2011 |
| Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism FS Menniti, JM Ren, TM Coskran, J Liu, D Morton, DK Sietsma, A Som, ... Journal of Pharmacology and Experimental Therapeutics 331 (3), 842-850, 2009 | 52 | 2009 |
| Prediction of Efficacy of Vabicaserin, a 5‐HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model J Liu, A Ogden, TA Comery, A Spiros, P Roberts, H Geerts CPT: Pharmacometrics & Systems Pharmacology 3 (4), 1-8, 2014 | 47 | 2014 |
| Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746 JD Gallezot, B Planeta, N Nabulsi, D Palumbo, X Li, J Liu, C Rowinski, ... Journal of Cerebral Blood Flow & Metabolism 37 (3), 1095-1107, 2017 | 45 | 2017 |
| Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients J Liu, E Kraut, J Bender, R Brooks, S Balcerzak, M Grever, H Stanley, ... Cancer Chemotherapy and Pharmacology 49, 367-374, 2002 | 43 | 2002 |
| Quantitative PK–PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans C Chang, W Byon, Y Lu, LK Jacobsen, LL Badura, A Sawant-Basak, ... The AAPS journal 13, 565-575, 2011 | 40 | 2011 |
| Challenges and opportunities in the development of medical therapies for pediatric populations and the role of extrapolation JS Barrett, R Bishai, C Bucci‐Rechtweg, A Cheung, S Corriol‐Rohou, ... Clinical Pharmacology & Therapeutics 103 (3), 419-433, 2018 | 37 | 2018 |
| Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility VP Reddy, M Kozielska, AA Suleiman, M Johnson, A Vermeulen, J Liu, ... Schizophrenia research 146 (1-3), 144-152, 2013 | 36 | 2013 |
| Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: A p hase 1, randomized controlled study D Mann, J Liu, ML Chew, H Bockbrader, CW Alvey, E Zegarac, J Pellock, ... Epilepsia 55 (12), 1934-1943, 2014 | 35 | 2014 |
| Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials VP Reddy, M Kozielska, M Johnson, AA Suleiman, A Vermeulen, J Liu, ... Clinical pharmacokinetics 51, 261-275, 2012 | 34 | 2012 |
| Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat J Liu, EH Kraut, S Balcerzak, M Grever, S D'Ambrosio, KK Chan Cancer chemotherapy and pharmacology 50, 445-453, 2002 | 33 | 2002 |
| Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12 CF Eisenbeis, GB Lesinski, M Anghelina, R Parihar, D Valentino, J Liu, ... Journal of Clinical Oncology 23 (34), 8835-8844, 2005 | 29 | 2005 |
| Exposure‐response analysis for spontaneously reported dizziness in pregabalin‐treated patient with generalized anxiety disorder K Ito, MM Hutmacher, J Liu, R Qiu, B Frame, R Miller Clinical Pharmacology & Therapeutics 84 (1), 127-135, 2008 | 27 | 2008 |
| Pharmacokinetic–pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score VP Reddy, M Kozielska, AA Suleiman, M Johnson, A Vermeulen, J Liu, ... Schizophrenia research 146 (1-3), 153-161, 2013 | 21 | 2013 |
| A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic … ER Nolan, MR Feng, JR Koup, J Liu, D Turluck, Y Zhang, JB Paulissen, ... Journal of pharmacological and toxicological methods 53 (1), 1-10, 2006 | 19 | 2006 |
| Linked Pharmacometric‐Pharmacoeconomic modeling and simulation in clinical drug development D Hill‐McManus, S Marshall, J Liu, RJ Willke, DA Hughes Clinical Pharmacology & Therapeutics 110 (1), 49-63, 2021 | 18 | 2021 |
| Pregabalin adjunctive therapy for focal onset seizures in children 1 month to< 4 years of age: a double‐blind, placebo‐controlled, video‐electroencephalographic trial D Mann, J Antinew, L Knapp, M Almas, J Liu, J Scavone, R Yang, ... Epilepsia 61 (4), 617-626, 2020 | 15 | 2020 |
| Pregabalin as adjunctive treatment for focal onset seizures in pediatric patients: a randomized controlled trial J Antinew, B Pitrosky, L Knapp, M Almas, V Pitman, J Liu, D Craiu, ... Journal of Child Neurology 34 (5), 248-255, 2019 | 13 | 2019 |
| A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors TS Bekaii-Saab, J Liu, KK Chan, SP Balcerzak, PS Ivy, MR Grever, ... Clinical cancer research 14 (11), 3434-3440, 2008 | 11 | 2008 |
